Stomach cancer: symptoms, diagnosis, treatments and nutrition after surgery

Stomach cancer, also called gastric cancer, usually means adenocarcinoma arising in the stomach lining. It requires tissue diagnosis and staging; treatment depends on the tumour type, extent, biology and the person’s health. Some early cancers can be removed endoscopically, while other cases need surgery and systemic treatment. Confidence is high in these diagnostic and care distinctions; no independent drug ranking or supplement cure is established here. Types of stomach tumour; Current NHS treatment context.

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

What is stomach cancer? Gastric adenocarcinoma and other tumours

The stomach receives food from the oesophagus and passes it to the small bowel. A tumour’s precise position matters, including whether it involves the junction with the oesophagus. Ask which organ and cell type the pathology identifies, rather than treating every upper-abdominal tumour as the same disease.

NCI distinguishes the usual adenocarcinoma from stomach GISTs, neuroendocrine tumours and lymphomas. These have different biology and treatment. A diagnosis that includes one of those names needs its own specialist explanation; this guide mainly describes adult gastric adenocarcinoma. Tumour-type distinction.

Symptoms, H. pylori and diagnosing gastric cancer

Symptoms can include indigestion or reflux, feeling full unusually quickly, reduced appetite, upper-abdominal discomfort, nausea and unexplained weight loss. Many noncancer conditions cause similar problems. A persistent change from your usual pattern needs review, particularly swallowing difficulty or worsening symptoms despite previous treatment. Symptoms and when to seek assessment.

H. pylori is a stomach infection associated with chronic inflammation and certain gastric cancers. Most infected people do not develop cancer. Infection, inflammation, a precancerous change and an invasive tumour are different findings. Discuss whether testing is appropriate; this guide does not choose antibiotics or propose blanket testing for every reader. Infection and cancer distinction.

Gastroscopy allows a clinician to examine the lining and take a biopsy. If cancer is found, scans and sometimes endoscopic ultrasound or a laparoscopy help assess its extent. Not every person needs every test. Ask what a planned procedure will resolve and when the result will be discussed. Diagnostic and staging pathway.

A tissue report and a stage answer different questions. Cell type describes the disease; stage describes how far it extends. Ask for both in writing, including any uncertainty. A normal symptom diary, improvement with an antacid or an internet risk score cannot replace the required investigation. Understanding stage.

Endoscopic removal, gastrectomy and systemic treatment

NCI describes endoscopic removal for selected very early lesions confined to the lining. Suitability depends on specialist assessment; it is not interchangeable with removing a larger or deeper tumour. Gastrectomy removes part or all of the stomach, with the reconstruction chosen for the tumour and operation. Endoscopic and surgical treatment context.

The NHS describes chemotherapy before or after surgery and other treatments in selected situations. Ask whether the aim is cure, lowering recurrence risk, disease control or relief of a particular symptom. The sequence and suitability depend on extent, health and recovery needs; a generic drug list cannot decide the plan. Treatment sequence and goals.

NCI’s professional summary describes targeted and immune-based treatments in selected gastric cancers, including biomarker-defined groups. Ask which tissue tests matter for the proposed treatment, whether there is enough sample and what the result would change. Supporting medicine trials were not cleared as independently funded, so no survival estimate or preferred product is adopted here. Tumour biology and treatment context.

If a tumour obstructs food passage, a stent or bypass may be considered to relieve the problem. The goal of such a procedure should be made explicit; improving food passage does not itself establish removal of all cancer. NCI also describes gastric HIPEC as being studied, which should not be presented as a proven universal standard. Obstruction relief and investigational treatment.

Nutrition after gastrectomy and supplement evidence

Removing stomach tissue changes the way food passes through the digestive system. NHS recovery guidance describes dietitian-led adjustment, smaller amounts of food, possible weight loss, diarrhoea, reflux and dumping syndrome, when food passes rapidly into the small bowel. Ask for a plan suited to the operation and your symptoms rather than copying another patient’s meal schedule. Life and nutrition after gastrectomy.

Possible vitamin deficiencies require review; some people need nutritional supplements or vitamin B12 injections. Ask which blood tests and replacements apply to the amount of stomach removed and who will continue long-term monitoring. Prescribed deficiency replacement has a different purpose from an advertised cancer-fighting vitamin. Deficiency and replacement context.

No independently verified restrictive diet or supplement cure is established here. Poor intake should prompt dietitian support, not a long list of excluded foods or unsupervised fasting. NCI distinguishes nutrition support from claims to eradicate or prevent recurrence of cancer. Diet and supplement limits.

Prevention, infection treatment and what evidence can show

The NHS identifies smoking, excess body weight and some dietary patterns among risk-related factors; age, family history and certain stomach conditions also matter. Prevention advice cannot tell an individual why cancer occurred. Discuss help with smoking and other modifiable risks without assuming that someone with cancer caused their illness. Risk and prevention context.

H. pylori assessment and treatment belong with a clinician. Reducing infection-related future risk is a different question from treating existing adenocarcinoma. Some gastric lymphomas have an infection-related treatment pathway, which must not be transferred to a different pathology. The older NCI fact sheet is used for this distinction, not current antibiotic selection or independently verified eradication efficacy. Infection-related disease context.

A detected tumour marker does not guarantee benefit from a matched medicine. Ask what is known for your exact tumour and stage, what alternatives exist and what uncertainty remains. Biomarker and inherited-risk testing also have different purposes. Limits of tumour-marker matching.

Bleeding, infection and postoperative emergencies

Vomiting blood needs medical advice. Seek emergency care when it occurs with faintness, confusion, rapid breathing, clammy skin, abdominal pain or black stools. A small-looking bleed or a previous diagnosis of gastritis is not a reason to ignore a new episode. Bleeding and emergency warning signs.

After gastrectomy, a clot, wound or chest infection, or a leak at the new digestive join can occur. Severe persistent abdominal pain, severe breathing difficulty or chest/upper-back pain requires emergency assessment. Fever, worsening breathlessness or wound discharge needs urgent contact with the surgical team or local urgent service. Postoperative warnings.

Cancer therapies can cause different side effects depending on the operation, radiation field and medicines. Ask which problems need routine review and which require the team’s urgent line. The NHS describes blood-count checks, infection risk, bleeding, bowel changes and some longer-lasting nerve or fertility effects with chemotherapy. Treatment monitoring and side effects.

During systemic treatment, contact the cancer team immediately for fever, shivering or other infection signs, following your written emergency instructions. Infection can become serious quickly. Do not wait for the next appointment or simply hide a fever with a nonprescription medicine. Urgent infection advice; Current NHS urgent contact advice.

Herbs, food interactions and altered medicine use

After surgery, ask the pharmacist whether swallowing, formulation or digestive changes affect the medicines you take. Never crush an anticancer tablet or switch a formulation without instructions. NCI’s interaction summary describes how herbs and foods can alter the handling of anticancer medicines. St John’s wort and grapefruit are examples that require an actual medicine check; the direction and size of an interaction vary. Do not assume every fruit, herb or drug behaves identically. Supplement and food interaction context.

Bring containers or photographs for vitamins, powders, teas, extracts and nonprescription medicines. Ask the oncology pharmacist which ingredients conflict with your treatment, surgery or symptom medicines. Do not stop an essential prescribed medicine or add a “protective” antioxidant based on a general internet warning.

Family history, pregnancy and individual assessment

Tell the team about stomach cancers in relatives and the ages when they occurred. Some hereditary syndromes can involve gastric cancer, but an ordinary family history does not establish a pathogenic gene variant. A genetics service should decide which testing and counselling are appropriate. Hereditary gastric conditions; Inherited-risk testing.

A tumour-only result is not automatically an inherited finding. Ask whether a result needs confirmation with germline testing and whether relatives would have any useful clinical action. A variant of uncertain significance should not be treated as a confirmed hereditary cancer diagnosis. Interpreting genetic results.

Before chemotherapy, raise pregnancy possibility, fertility wishes, other illnesses and difficulty keeping food or fluids down. The care plan needs to account for treatment burden as well as tumour extent. A regimen that is familiar on the internet may not be safe for the person considering it. Fertility and treatment precautions.

Planning treatment, nutrition and long-term follow-up

Bring the biopsy report, scan reports and a complete medicine and supplement list. Ask the team to identify the primary site, cell type, stage and tests still awaited. Clarify who is coordinating decisions across endoscopy, surgery, oncology and nutrition services.

If surgery is proposed, ask how much stomach will be removed, how the digestive tract will be reconnected and which eating problems are anticipated. Request a written route for dietitian review and nutritional monitoring after hospital discharge. Explain if meal preparation, cost or help at home is difficult.

Report ongoing weight loss, food sticking, dizziness or cramps after eating and persistent reflux. Ask whether the explanation has been established and whether another examination is needed. Recovery instructions are not permission to dismiss a new or worsening symptom. Problems to report during recovery.

Clarify how response and recurrence will be assessed, including the purpose of each follow-up test. Request an urgent-contact number and an explanation of who answers outside normal hours. If a symptom changes between visits, use that plan instead of waiting for a routine scan.

Supportive and palliative care can address pain, eating difficulties, emotional distress and family needs alongside anticancer treatment. Asking for this support does not decide whether treatment is curative or imply a single prognosis. Discuss the immediate priorities and the help needed to meet them. Support alongside cancer care.

Animal and laboratory gastric-cancer evidence

Killing gastric cancer cells in a dish or shrinking a tumour in an animal does not establish a safe human cancer treatment. Laboratory mechanisms can help plan research, but a clinical claim needs the relevant human tumour subtype, comparison, outcomes, harms and financial disclosures. No animal or in-vitro finding enters this guide as proof of cure, survival benefit or a supplement regimen.

Funding and source roles

The clinical descriptions are attributed to the actually opened NCI and NHS originals. NCI’s budget and gift authority and the national NHS’s accounts/content policy were checked. PDQ’s editorial separation does not establish independence of every board member or drug trial; the policy does not request specific board conflict disclosure. The NHS stomach series was reviewed in August 2026, while gastrectomy information is March 2025. H. pylori information is explicitly dated April 2023 and is not used for current antibiotic policy. No manufacturer-funded outcome is adopted as an independent efficacy verdict. Grades are provisional editorial assessments, separate from method quality and guideline certainty.

Frequently asked questions

Is stomach cancer always adenocarcinoma?

No. A stomach mass can have a different cell type, including GIST, lymphoma or a neuroendocrine tumour.

Does persistent indigestion mean cancer?

No. Several conditions can cause it, but persistent or changed symptoms need assessment.

Can H. pylori antibiotics cure gastric adenocarcinoma?

They do not replace the treatment of an established adenocarcinoma.

Can someone eat after their whole stomach is removed?

The digestive tract is reconstructed, with ongoing adjustment and nutritional support.

Are vitamins after surgery an anticancer treatment?

Deficiency replacement has a nutritional purpose and needs an individual monitoring plan.

Does every stomach cancer need the same operation?

No. Location, depth, spread and health influence the options.

Is HIPEC routinely proven for every gastric cancer?

No. This guide describes it as an investigational context, not a universal standard.

What should a follow-up plan include?

Who monitors response and nutrition, what symptoms to report and how to obtain urgent advice.

Sources and funding notes

Actual NHS symptoms/risk/tests/treatment originals reviewed 20 August 2026; actual gastrectomy recovery and complications reviewed 12 March 2025. NCI gastric patient treatment updated 10 April 2025 and professional PDQ 21 February 2025; cell types, treatment roles and selected marker context checked, not supporting trial efficacy. Patient drug-menu item regorafenib was not generalized to adenocarcinoma, and no exhaustive current drug menu was reproduced. H. pylori fact sheet reviewed 12 April 2023; infection distinction used, current testing/antibiotic eligibility and trial funding unclosed. Vomiting-blood warning original reviewed 18 August 2025. Public finance/PDQ recusal and honoraria checked; complete donor ledger, exact source allocation, author and underlying medicine/infection trial finances not established. No personal doses or prognostic percentages.

1. NHS: stomach cancer symptoms — Changed upper-digestive symptoms and prompt review.
2. NHS: stomach cancer risk — H. pylori, family history and prevention context; no blame or individual prediction.
3. NHS: stomach cancer tests — Gastroscopy, biopsy and staging examination roles.
4. NHS: stomach cancer treatment — Stage- and health-dependent clinical treatment context.
5. NCI: stomach cancer types — Adenocarcinoma versus GIST, neuroendocrine tumours and lymphoma.
6. NCI: stomach cancer patient treatment — Gastrectomy, selected endoscopic treatment, obstruction relief and investigational HIPEC context.
7. NCI PDQ: gastric cancer professional summary — Cell types, multidisciplinary decisions and tumour-biomarker context; no drug outcome estimate.
8. NCI: H. pylori and cancer — Chronic infection/cancer distinction; not current antibiotic guidance or an independent eradication-trial verdict.
9. NHS: recovery after gastrectomy — Dietitian-led recovery, altered digestion and possible deficiency replacement.
10. NHS: gastrectomy complications — Postoperative clot, infection, leak and emergency warnings.
11. NHS: vomiting blood — Urgent bleeding and emergency deterioration signs.
12. NCI: diets and supplements, October 2024 — Nutrition support and lack of an established dietary/supplement cure.
13. NCI PDQ: cancer therapy and supplement interactions, April 2024 — Safety discussion; no universal interaction severity or cure estimate.
14. NCI: infection during treatment, January 2020 — Urgent infection context, corroborated by current NHS chemotherapy advice; no new regimen.
15. NCI: tumour biomarker testing, December 2021 — Somatic versus inherited testing and uncertainty; no current product list or assay performance claim.
16. NCI: inherited cancer risk testing, April 2024 — Counselling and family-risk distinction; local eligibility and services require confirmation.
17. NCI: cancer staging, October 2022 — Extent of disease versus tumour biology; no personal stage assignment.
18. NCI: palliative care, November 2021 — Supportive care alongside cancer treatment; underlying outcomes and society conflicts not cleared.
19. NHS: chemotherapy, February 2025 — Monitoring, side effects, urgent team contact, fertility and pregnancy context.
20. NCI: clinical trials information hub — Sponsor, comparison, consent and participation questions; no individual trial benefit established.
21. NCI FY2025 budget, June 2026 — Institutional appropriation/reimbursement provenance; not treatment evidence.
22. NCI original gift agreements, April 2018 — Actual statutory institutional gift channel and ethics review; current donor ledger unresolved.
23. NCI PDQ editorial process, November 2022 — Honoraria, editorial roles, recusal and specific-disclosure limitation.

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.